Navigation Links
Partnering Deals and Alliances with Big Pharma
Date:7/9/2013

, including:
Partnering interests and indications
Partnering activity since 2007
Partner companies since 2007
Partnering activity since 2007 by:
Partner company
Deal type
Industry sector
Stage of development
Technology type
Therapy area
Over 300 charts showing the dealmaking activity of each company since 2007
The tools to enable effective and efficient preparation for partnering negotiation with big pharma
3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
The leading M&A and partnering deals by value 2007-2013

The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available contract documents for each of the fifty big pharma companies.

Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

•Detailed partnering activity profiles for each of the top 50 big pharma com
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Cancer Vaccine Partnering Terms and Agreements
2. Richard Atkin to Join MedTech Nordic Investing & Partnering 2013
3. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
4. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
5. Life Science Veterans Highlight Opportunities at BIOCOM 3rd Annual Global Partnering Conference
6. The Michael J. Fox Foundation Announces Fourth Quarter Participants in Partnering Program Between Awardees and Industry
7. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
8. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
9. Vaccine Partnering Terms and Agreements
10. Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals
11. TopProdeals.com Rises to Top as Discount Dental Supply Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: ... of proof-of-concept (POC) for CCP-08, the third programme ... cough cold collaboration. Under this collaboration, POC requires ... successful human pilot comparative study against an immediate ... POC, Vernalis will make a milestone payment to ...
(Date:7/21/2014)... , July 21, 2014 McCord ... patent (U.S. Patent No. 8,796,315). This patent describes ... wound healing.  According to the inventor, Dr. McCord, ... who require wound healing, a composition of an ... derived from umbilical cord blood, such that the ...
(Date:7/21/2014)... , July 21, 2014  EHE International, the recognized ... a nationwide physician network, today announced that Dignity Health ... NV has been named an EHE-certified preventive ... Las Vegas region now have greater ... maintain their health. "EHE is proud ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:7/22/2014)... Cloud+MD Office 2.0 is a ... medical software and services, designed by experienced healthcare ... “Actionable Information” to help Independent Physician Practices, New ... Services optimize a wide range of business processes ... Noticeable Cost Reductions and Better Patient Care. ...
(Date:7/22/2014)... An Ideal Location , Narconon Arrowhead, ... naturally tranquil and very beautiful Arrowhead State Park, overlooking ... for both a rehabilitative setting, as well as a ... of fireworks. Launched over the waters of the ... in the lake, or from the nearby campgrounds and ...
(Date:7/22/2014)... 22, 2014 MonaVie announces today that ... Advisory Board (SAB). The addition of Macdonald will help ... current product development plans and necessary substantiation for research ... Macdonald has been with the company as its nutrition ... helping formulate MonaVie’s RVL and CORE ...
(Date:7/22/2014)... 22, 2014 Joining Conquer Paralysis Now as ... the next decade is Paralympic silver medalist and quadriplegic Jennifer ... became a quadriplegic from a spinal cord injury in 1998. ... a cure for paralysis. , “People define cure differently,” French ... something else. We have the image in our minds of ...
(Date:7/22/2014)... Beach, Florida (PRWEB) July 22, 2014 ... alcohol treatment center located in Pompano Beach, ... approval from the Joint Commission, an independent not-for-profit ... United States. Accreditation signifies that the quality programs ... Joint Commission standards for safety and performance. Ocean ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:Narconon Arrowhead Holds Annual Firework Event 2Health News:Narconon Arrowhead Holds Annual Firework Event 3Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3
... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: